The Latest News about Atezolizumab Approval in Metastatic TNBC

Atezolizumab (Tecentriq), the first in class anti-PD-L1 antibody was the first immunotherapy given accelerated approval for metastatic TNBC (mTNBC) in March 2019. This was the first immune checkpoint inhibitor approved for breast cancer, and rapidly changed the standard of care … Continue reading The Latest News about Atezolizumab Approval in Metastatic TNBC